"Colombia Pharmaceuticals & Healthcare Report Q4 2015" now available at Fast Market Research

A growing burden of chronic diseases, along with the Colombian government's push toward improving its national healthcare system will ensure the country's retained appeal to multinational drugmakers and healthcare suppliers. Despite remaining concerns surrounding Colombia's counterfeit drug market, the country's overwhelming demand for medical access will keep health and medicine spending on a positive trajectory over the long term.

Headline Expenditure Projections

Pharmaceuticals: COP8,643bn (USD4.3bn) in 2014 to COP9,110bn (USD3.6bn) in 2015; +5.4% in local currency terms. F orecast revised upward from Q 2 15 due to historical data.

Healthcare: COP53,417bn (USD26.7bn) in 2014 to COP57,414bn (USD22.4bn) in 2015; +7.5% in local currency terms. Forecast revised upward from Q 2 15 due to historical data.

Full Report Details at
- http://www.fastmr.com/prod/1032883_colombia_pharmaceuticals.aspx?afid=302

Risk/Reward Index

In our Q415 regional Risk/Reward Index, Colombia has maintained seventh place out of 19 markets surveyed in the Americas region. The country's overall Risk/Reward score was 50.3, just above the regional average of 48.7. Colombia boasts above-average Rewards and Risks, although we caution that the country's intellectual property regime will continue to represent barriers to multinational involvement. Nevertheless, Colombia will continue to be of interest from a longer term point of view, not least on account of its substantial population numbers.

Key Trends and Developments

July

A commission of German experts, led by Parliamentarian Karl Lauterbach, visited Colombia to share their expertise on their home country's social security system. The delegation participated in a forum titled 'Germany Colombia: similar health systems, a lot to learn,' an initiative of Colombia's health and social protection ministry.

The Colombia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Colombia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Colombia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Colombia, to test other views - a key input for successful budgeting and strategic business planning in the Colombian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Colombian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Colombia.
*

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q4 2015
- Kenya Pharmaceuticals & Healthcare Report Q4 2015
- Pakistan Pharmaceuticals & Healthcare Report Q4 2015
- Mexico Pharmaceuticals & Healthcare Report Q4 2015
- Hungary Pharmaceuticals & Healthcare Report Q4 2015